FREE MEMBERSHIP Includes » ABL Advisor eNews + iData Blasts | JOIN NOW ABLAdvisor Gray ABLAdvisor Blue
 
Skip Navigation LinksHome / News / Read News

Print

DCF Advises Advanced Pharma on Sale to Avella Specialty Pharmacy

February 06, 2017, 08:00 AM
Filed Under: Pharmaceuticals

Deloitte Corporate Finance LLC acted as financial advisor to Houston-based Advanced Pharma, Inc. (Advanced Pharma) on its sale to Avella Specialty Pharmacy (Avella). Advanced Pharma is an FDA-registered 503B Outsourcing Facility providing compounded products to hospitals, health systems and ambulatory surgery centers nationwide. The transaction closed Dec. 1, 2016.

Advanced Pharma maintains a state-of-the-art, 35,000-square-foot production facility with rigorous quality controls. Advanced Pharma’s extensive product portfolio, differentiated production capabilities and stringent compliance standards have enabled it to meet the growing demand for customized pharmaceuticals across the U.S. The transaction will support Advanced Pharma’s continued national growth and expansion into new therapeutic classes.

“We could not be more pleased by the outcome of this transaction. Avella is an excellent partner with extensive resources and expertise that we can leverage to continue our growth trajectory,” said Bourjois Abboud, founder and CEO of Advanced Pharma, Inc. “Deloitte Corporate Finance was instrumental in guiding us through all aspects of the process and helping us position the company for an optimal outcome.”

“Advanced Pharma has established a reputation for quality and excellence and we were excited to advise them through this process,” said Jason Porter, senior vice president, Deloitte Corporate Finance LLC. “Our team is looking forward to seeing the combined capabilities of an Advanced Pharma – Avella partnership and the creation of a leading national provider of compounded sterile preparations.”







Comments From Our Members

You must be an ABL Advisor member to post comments. Login or Join Now.